Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deferitrin

Next Previous
Drug Profile

Deferitrin

Alternative Names: GT 56-252; Iron chelator - Sanofi Genzyme

Latest Information Update: 15 Dec 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genzyme Corporation
  • Class Carboxylic acids; Small molecules; Thiazoles
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Iron overload
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Iron overload

Most Recent Events

  • 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
  • 31 Dec 2010 This programme is still active
  • 30 Nov 2005 Genzyme has completes a phase I/II trial in Iron overload in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top